Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Sandoz's Exelon shows positive results in phase III

Aug. 9, 1996

NMDA antagonists claimed by E. Merck

Aug. 9, 1996

Dainippon's new compound superior to metoclopramide for digestive function improvement

Aug. 9, 1996

Teva's Copaxone progresses toward FDA approval

Aug. 9, 1996

5-HT1A agonist with alpha1-adrenoceptor-blocking properties from Byk Gulden

Aug. 9, 1996

Multiuse melatonergic 3-alkoxybenzylpiperidine derivatives from Bristol-Myers Squibb

Aug. 9, 1996

ADIR describes compunds with high affinity for 5-HT2C and/or 5-HT3C receptors

Aug. 9, 1996

Lidocaine nasal drops shown effective for fast migraine pain relief

Aug. 9, 1996

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...